Medicine & Life Sciences
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
16%
Acute Myeloid Leukemia
100%
Acute Promyelocytic Leukemia
37%
AG-221
9%
Allogeneic Cells
13%
BI 6727
9%
Blast Crisis
9%
bosutinib
66%
Chromosome Mapping
18%
Comorbidity
9%
Coronavirus
20%
Cytogenetics
10%
Dasatinib
14%
Drug Therapy
11%
Elderly
18%
Essential Thrombocythemia
13%
Fluorescence In Situ Hybridization
9%
Genes
15%
Graft vs Host Disease
10%
Hematopoietic Stem Cells
13%
High-Throughput Nucleotide Sequencing
9%
Imatinib Mesylate
31%
INCB018424
15%
Indoleamine-Pyrrole 2,3,-Dioxygenase
13%
Jehovah's Witnesses
15%
Leukemia
18%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
88%
Leukemia, Myeloid, Chronic Phase
58%
Mortality
24%
Multiple Myeloma
11%
Myelodysplastic Syndromes
12%
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
9%
Neoplasms
17%
Phase III Clinical Trials
15%
Philadelphia Chromosome
13%
Physicians
13%
Polymerase Chain Reaction
11%
Population
10%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10%
Protein-Tyrosine Kinases
74%
Rhabdomyolysis
12%
Safety
14%
Saliva
17%
SARS Virus
42%
Severe Acute Respiratory Syndrome
19%
Stem Cell Transplantation
13%
Survival
23%
Therapeutics
31%
Transplants
14%
venetoclax
23%